Revance Therapeutics, Inc.
NASDAQ:RVNC
3.06 (USD) • At close December 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 234.04 | 132.565 | 77.798 | 15.325 | 0.413 | 3.729 | 0.262 | 0.3 | 0.3 | 0.383 | 0.617 | 0.717 | 0.557 |
| Cost of Revenue
| 152.163 | 51.667 | 23.41 | 4.769 | 102.861 | 92.5 | 0 | 0 | 1.995 | 0 | 0 | 0 | 0.005 |
| Gross Profit
| 81.877 | 80.898 | 54.388 | 10.556 | -102.448 | -88.771 | 0.262 | 0.3 | -1.695 | 0.383 | 0.617 | 0.717 | 0.552 |
| Gross Profit Ratio
| 0.35 | 0.61 | 0.699 | 0.689 | -248.058 | -23.806 | 1 | 1 | -5.65 | 1 | 1 | 1 | 0.991 |
| Reseach & Development Expenses
| 79.41 | 101.286 | 116.255 | 125.795 | 102.861 | 92.5 | 80.361 | 50.381 | 47.529 | 33.39 | 27.831 | 32.708 | 22.735 |
| General & Administrative Expenses
| 38.814 | 4.238 | 28.307 | 149.743 | 62.011 | 53.863 | 37.398 | 29.075 | 25.088 | 19.043 | 11.011 | 0 | 0 |
| Selling & Marketing Expenses
| 253.424 | 183.101 | 166.42 | 2.103 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 292.238 | 223.934 | 198.821 | 151.846 | 62.011 | 53.863 | 37.398 | 29.075 | 25.088 | 19.043 | 11.011 | 11.195 | 5.555 |
| Other Expenses
| 27.006 | 27.847 | 13.988 | 6.077 | -0.303 | -0.773 | -0.525 | -0.535 | -0.327 | -0.234 | -0.404 | -0.106 | 0.17 |
| Operating Expenses
| 398.654 | 353.067 | 329.064 | 283.718 | 164.872 | 146.363 | 117.759 | 79.456 | 72.617 | 52.433 | 38.842 | 43.903 | 28.29 |
| Operating Income
| -316.777 | -272.169 | -274.676 | -273.162 | -164.459 | -142.634 | -120.424 | -88.215 | -72.317 | -52.05 | -38.225 | -43.186 | -27.738 |
| Operating Income Ratio
| -1.354 | -2.053 | -3.531 | -17.825 | -398.206 | -38.25 | -459.634 | -294.05 | -241.057 | -135.901 | -61.953 | -60.232 | -49.799 |
| Total Other Income Expenses Net
| -6.909 | -13.764 | -6.634 | -11.547 | 5.03 | 3.066 | -0.163 | -1.055 | -1.159 | -10.867 | -14.223 | -15.073 | -17.125 |
| Income Before Tax
| -323.686 | -355.722 | -281.31 | -284.709 | -159.429 | -139.568 | -120.587 | -89.27 | -73.476 | -62.917 | -52.448 | -58.259 | -44.863 |
| Income Before Tax Ratio
| -1.383 | -2.683 | -3.616 | -18.578 | -386.027 | -37.428 | -460.256 | -297.567 | -244.92 | -164.274 | -85.005 | -81.254 | -80.544 |
| Income Tax Expense
| 0.3 | 0.7 | 5.514 | -2.62 | -3.212 | 3 | -1.536 | -0.898 | -1.132 | 8.387 | 12.879 | 28.853 | 17.96 |
| Net Income
| -323.986 | -356.422 | -286.824 | -282.089 | -156.217 | -142.568 | -120.587 | -89.27 | -73.476 | -62.917 | -52.448 | -58.259 | -44.863 |
| Net Income Ratio
| -1.384 | -2.689 | -3.687 | -18.407 | -378.249 | -38.232 | -460.256 | -297.567 | -244.92 | -164.274 | -85.005 | -81.254 | -80.544 |
| EPS
| -3.83 | -4.9 | -4.25 | -4.86 | -3.59 | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 | -2.96 | -8.12 | -6.25 |
| EPS Diluted
| -3.83 | -4.9 | -4.25 | -4.86 | -3.59 | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 | -2.96 | -8.12 | -6.25 |
| EBITDA
| -290.637 | -305.516 | -255.184 | -259.31 | -156.52 | -137.798 | -118.662 | -86.743 | -70.291 | -49.999 | -35.403 | -27.523 | -25.09 |
| EBITDA Ratio
| -1.242 | -1.823 | -3.356 | -17.185 | -385.545 | -37.378 | -445.084 | -261.737 | -241.377 | -136.397 | -62.605 | -57.891 | -45.907 |